223
Views
9
CrossRef citations to date
0
Altmetric
Review

The effect of intravitreal injections on dry eye, and proposed management strategies

, , &
Pages 1491-1497 | Published online: 16 Aug 2017

References

  • MiljanovicBDanaRSullivanDASchaumbergDAImpact of dry eye syndrome on vision-related quality of lifeAm J Ophthalmol2007143340941517317388
  • CalongeMEnriquez-de-SalamancaADieboldYDry eye disease as an inflammatory disorderOcul Immunol Inflamm201018424425320482396
  • YehSSongXJFarleyWLiDQSternMEPflugfelderSCApoptosis of ocular surface cells in experimentally induced dry eyeInvest Ophthalmol Vis Sci200344112412912506064
  • CongdonNGFriedmanDSLietmanTImportant causes of visual impairment in the world todayJAMA2003290152057206014559961
  • MukamalR webpage on the InternetAvastin, Eylea and Lucentis – What’s the Difference?2015 Available from: http://www.aao.org/eye-health/diseases/avastin-eylea-lucentis-differenceAccessed November 14, 2016
  • YancopoulosGDClinical application of therapies targeting VEGFCell20101431131620887885
  • FerraraNHillanKJGerberHPNovotnyWDiscovery and development of bevacizumab, an anti-VEGF antibody for treating cancerNat Rev Drug Discov20043539140015136787
  • FerraraNDamicoLShamsNLowmanHKimRDevelopment of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degenerationRetina200626885987017031284
  • RosenfeldPJBrownDMHeierJSMARINA Study GroupRanibizumab for neovascular age-related macular degenerationN Engl J Med2006355141419143117021318
  • BrownDMKaiserPKMichelsMANCHOR Study GroupRanibizumab versus verteporfin for neovascular age-related macular degenerationN Engl J Med2006355141432144417021319
  • SrinageshVEllenbergDScharperPHEtterJIntravitreal Dry Eye StudyInvest Ophthalmol Vis Sci2014551336963696
  • GargPRoyASharmaSEndophthalmitis after cataract surgery: epidemiology, risk factors, and evidence on protectionCurr Opin Ophthalmol2017281677227661662
  • MantelliFTranchinaLLambiaseABoniniSOcular surface damage by ophthalmic compoundsCurr Opin Allergy Clin Immunol201111546447021822131
  • AyakiMIwasawaANiwanoYIn vitro assessment of the cytotoxicity of six topical antibiotics to four cultured ocular surface cell linesBiocontrol Sci2012172939922790846
  • MencucciRPaladiniIPellegrini-GiampietroDEMenchiniUScartabelliTIn vitro comparison of the cytotoxic effects of clinically available ophthalmic solutions of fluoroquinolones on human kerato-cytesCan J Ophthalmol201146651352022153639
  • AbelsonMB webpage on the InternetIodine: An Elemental Force against Infection2009 Available from: https://www.reviewofophthal-mology.com/article/iodine-an-elemental-force-against-infectionAccessed July 3, 2017
  • SpeakerMGMenikoffJAProphylaxis of endophthalmitis with topical povidone-iodineOphthalmology19919812176917751775308
  • Mino de KasparHChangRTSinghKEgbertPRBlumenkranzMSTaCNProspective randomized comparison of 2 different methods of 5% povidone-iodine applications for anterior segment intraocular surgeryArch Ophthalmol2005123216116515710810
  • JiangJWuMShenTThe toxic effect of different concentrations of povidone iodine on the rabbit’s corneaCutan Ocul Toxicol200928311912419694608
  • NaorJSavionNBlumenthalMAssiaEICorneal endothelial cytotoxicity of diluted povidone – iodineJ Cataract Refract Surg200127694194711408145
  • PelsEVrensenGFMicrobial decontamination of human donor eyes with povidone-iodine: penetration, toxicity, and effectivenessBr J Ophthalmol19998391019102610460768
  • ShibataYTanakaYTomitaTEvaluation of corneal damage caused by iodine preparations using human corneal epithelial cellsJpn J Ophthalmol201458652252725230910
  • WerdichXRuezTSinghRPrevalence and severity of blepharitis symptoms and signs amongst patients with age-related macular degenerationInvest Ophthalmol Vis Sci2010511351225122
  • LiXMZhaoXHuLZWangWClinical observation of dry eye in patients before and after cataract surgeryZhonghua yan ke za zhi [Chin J Ophthalmol]20074311013 Chinese
  • BaudouinCAragonaPMessmerEMRole of hyperosmolarity in the pathogenesis and management of dry eye disease: proceedings of the OCEAN group meetingOcul Surf201311424625824112228
  • VersuraPProfazioVCamposECPerformance of tear osmolarity compared to previous diagnostic tests for dry eye diseasesCurr Eye Res201035755356420597641
  • JacobiCJacobiAKruseFECursiefenCTear film osmolarity measurements in dry eye disease using electrical impedance technologyCornea201130121289129222001814
  • AlfieriRRCavazzoniAPetroniniPGCompatible osmolytes modulate the response of porcine endothelial cells to hypertonicity and protect them from apoptosisJ Physiol2002540pt 249950811956339
  • CammarataPRSchaferGChenSWGuoZReevesREOsmoregulatory alterations in taurine uptake by cultured human and bovine lens epithelial cellsInvest Ophthalmol Vis Sci200243242543311818387
  • KaercherTBuchholzPKimmichFTreatment of patients with keratoconjunctivitis sicca with Optive™: results of a multicenter, open-label observational study in GermanyClin Ophthalmol20093333919668542
  • The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007)Ocul Surf200752759217508116
  • HessenMAkpekEKDry eye: an inflammatory ocular diseaseJ Ophthalmic Vis Res20149224025025279127
  • NelsonJDWrightJCConjunctival goblet cell densities in ocular surface diseaseArch Ophthalmol19841027104910516378156
  • XuMSivakJGMcCannaDJComparison of the effects of ophthalmic solutions on human corneal epithelial cells using fluorescent dyesJ Ocul Pharmacol Ther201329979480223905770
  • DuaHSAzuara-BlancoALimbal stem cells of the corneal epitheliumSurv Ophthalmol200044541542510734241